Bureau of Insurance of SCC; step therapy protocols for health benefit plans, report.
Summary
HB2258 directs the Virginia Bureau of Insurance, within the State Corporation Commission, to study step therapy protocols used by health benefit plans. The study must be based on a data call to health carriers and must collect information on the number of step therapy exception requests, approvals, denials, appeals, and reversals; the timing of responses and final decisions; how often protocols are added, revised, or removed; and the medical specialties most affected, including areas such as oncology, rheumatology, ophthalmology, orthopedics, and neurosurgery.
The bill is a reporting measure rather than a direct regulatory change. It requires the Bureau to prepare an executive summary and a report with findings and recommendations for the Governor and General Assembly by November 1, 2026, with posting on the General Assembly website by the start of the 2027 Regular Session. Its practical effect is to create a formal information-gathering process that could inform future legislation or administrative action on step therapy in health insurance.
Impact
HB2258 does not itself change insurance coverage rules or step therapy standards in the Code of Virginia; instead, it adds a new study and reporting obligation for the Bureau of Insurance under the State Corporation Commission. The bill affects health carriers that offer health benefit plans by requiring them to respond to a data call and provide detailed utilization and timing data on step therapy exception processes. The resulting report may influence future policy decisions affecting insurers, patients, and providers in specialty care fields.
Sentiment
The bill appears to have broad overall support, as reflected by strong vote margins in both chambers. It passed the House 88-9 and the Senate 40-0, suggesting general agreement that the state should gather more information on how step therapy protocols operate and affect patients. Earlier committee and subcommittee votes were also favorable, though not unanimous, indicating some initial hesitation before the measure advanced with a substitute.
Contention
The main point of contention appears to have been whether the state should require this level of reporting from health carriers and whether a study is the appropriate response to concerns about step therapy. The non-unanimous subcommittee and committee votes in the House suggest some members may have questioned the need for additional administrative burden or the value of a study versus direct reform. However, the absence of recorded Senate opposition and the final strong passage indicate that any objections were limited and did not prevent enactment.